Breaking news on huntingtons disease
Onset Of Huntington's Delayed By Physical Activity In Mouse Model published
Tue, 01 Apr 2008 04:00:00 PDT
The simple act of running in an exercise wheel delays the onset of some symptoms of Huntington's disease in a mouse model of the fatal human disorder according to research published in the open-access journal BMC Neuroscience. These findings add insights into the pathogenesis of the disease and suggest possible preventive therapeutic targets.Huntington's disease affects up to one person in every 10 000, but clusters in families and certain populations.
Sirtris Pharmaceuticals Scientific Advisor Shows SIRT1 Activation Improves Huntington's Disease In Preclinical Model published
Mon, 31 Mar 2008 04:00:00 PDT
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced that Sirtris Scientific Advisory Board Co-Chair Leonard P.
Promising New Drug Targets Identified For Huntington's Disease published
Mon, 24 Mar 2008 04:00:00 PDT
Research funded by the Wellcome Trust has provided a number of promising new drug targets for Huntington's disease, a neurodegenerative disease. Scientists at the University of Cambridge have identified a number of candidate drugs to investigate further which encourage cells to "eat" the malformed proteins that lead to the disease.
Avicena's HD-02 To Proceed To NIH Sponsored Phase III Huntington's Disease Trial published
Thu, 13 Mar 2008 00:00:00 PDT
Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced that it met with the Food and Drug Administration (FDA) and will proceed with a Phase III trial of its lead drug candidate, HD-02, for the treatment of Huntington's disease, pending final analysis of completed animal toxicology studies.
Huntington's Disease Broken Down One Protein At A Time published
Tue, 05 Feb 2008 05:00:00 PDT
Hoping to piece together the intricate series of interactions that lead to Huntington's disease, Indiana University Bloomington scientists have determined the shape and structure of a binding site that may prove useful in combating the neurodegenerative disease.In the Feb.
Potential New Treatments For Huntington's Disease published
Thu, 10 Jan 2008 03:00:00 PDT
Working with fruit flies, researchers have discovered a new mechanism by which the abnormal protein in Huntington's disease causes neurodegeneration. They have also manipulated the flies to successfully suppress that neurodegeneration, which they said suggests potential treatments to delay the onset and progression of the disease in humans.Juan Botas and colleagues published their findings in the January 10, 2008, issue of the journal Neuron, published by Cell Press.
Evidence Of Early Start In Huntington's Disease published
Thu, 10 Jan 2008 03:00:00 PDT
The damaging effects of the mutated protein involved in Huntington's disease take place earlier in cell life than previously believed, said researchers from Baylor College of Medicine in Houston in a report that appears in the current edition of the journal Neuron."This research provides evidence of toxicity by huntingtin (the protein involved in the disease) early during the disease process," said Dr. Juan Botas, associate professor of molecular and human genetics at BCM.
Data On Avicena's Drug Candidate HD-02 Presented At The 2007 World Congress On Huntington's Disease published
Tue, 20 Nov 2007 00:00:00 PDT
Avicena Group, Inc. (OTCBB: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that Drs. Steven Hersch and Diana Rosas presented results regarding the Company's novel Huntington's disease treatment candidate HD-02 at the 2007 World Congress on Huntington's Disease in Dresden, Germany. Drs.
Evidence Of 'Memory' In Cells And Molecules Shown By Researchers published
Tue, 30 Oct 2007 06:00:00 PDT
Research reported October 29 in the journal Proceedings of the National Academy of Sciences (PNAS) provides evidence that some molecular interactions on cell surfaces may have a "memory" that affects their future interactions. The report could lead to a re-examination of results from certain single-molecule research.
CombinatoRx Receives Huntington's Disease Society Leadership Award published
Wed, 24 Oct 2007 05:00:00 PDT
CombinatoRx, Incorporated (NASDAQ: CRXX) announced that it has received the Marjorie Guthrie Leadership Award from the Huntington's Disease Society of America (HDSA) during their 40th Anniversary Guthrie Awards Dinner in New York City to benefit the Woody and Marjorie Guthrie Research fund. Alexis Borisy, President and CEO of CombinatoRx was present to accept the award.
Animal Study Identifies Potential Treatment For Huntington's Disease published
Fri, 19 Oct 2007 02:00:00 PDT
MassGeneral Institute for Neurodegererative Disease (MIND) researchers have identified a compound that may lead to a treatment that could protect against the effects of Huntington's Disease (HD). Their report, which will appear in the Proceedings of the National Academy of Sciences, describes how a small molecule called C2-8 appears to delay the loss of motor control and reduce neurological damage in a mouse model of the disorder. The study is receiving early online release.
Potential Treatment For Huntington's Disease Identified published
Tue, 09 Oct 2007 01:00:00 PDT
MassGeneral Institute for Neurodegererative Disorders (MIND) researchers have identified a compound that may lead to a treatment that could protect against the effects of Huntington's Disease (HD). Their report, which will appear in the Proceedings of the National Academy of Sciences, describes how a small molecule called C2-8 appears to delay the loss of motor control and reduce neurological damage in a mouse model of the disorder. The study is receiving early online release.
New Avenue Of Research Against Huntington's Disease published
Thu, 27 Sep 2007 12:00:00 PDT
Paying close attention to how a canary learns a new song has helped scientists open a new avenue of research against Huntington's disease -- a fatal disorder for which there is currently no cure or even a treatment to slow the disease.In a paper published in the Journal of Clinical Investigation, scientists at the University of Rochester Medical Center have shown how stem-cell therapy might someday be used to treat the disease.
Huntington's Disease Linked To Health Benefits In Young By Tufts University Biologists published
Thu, 27 Sep 2007 10:00:00 PDT
For years researchers in neurology have believed that people with Huntington's disease have more children than the general population because of behavioral changes associated with the disease that lead to sexual promiscuity. In a new Tufts University study, three biologists have challenged that notion by suggesting that people with Huntington's have more children because they are healthier -- not more promiscuous -- during their peak reproductive years.
Breakthrough In Huntington's Research published
Sun, 26 Aug 2007 02:00:00 PDT
A major breakthrough in the understanding and potential treatment of Huntington's disease has been made by scientists at the University of Leeds.Researchers in the University's Faculty of Biological Sciences have discovered that one of the body's naturally occurring proteins is preventing 57 genes from operating normally in the brains of Huntington's sufferers.
New Drug Target For Huntington's Disease published
Wed, 22 Aug 2007 09:00:00 PDT
McMaster University researchers have first insight into how Huntington's disease (HD) is triggered. The research is published online in the British Journal, Human Molecular Genetics."These are exciting results by the McMaster team," said Dr. RĂ©mi Quirion, Scientific Director at the Canadian Institutes of Health Research, Institute of Neuroscience, Mental Health and Addiction.
Alnylam And Medtronic Advance Collaboration On Drug-Device Combinations With RNAi Therapeutics For CNS Diseases published
Fri, 03 Aug 2007 02:00:00 PDT
Medtronic, Inc., (NYSE: MDT) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced that the companies are advancing their collaboration initiated in February, 2005, following positive pre-clinical data generated under the initial joint technology development phase of the program. Under the terms of the agreement, Alnylam and Medtronic will focus on developing a drug-device combination for the treatment of Huntington's disease.
Animal Models Of Huntington's Disease On Target published
Thu, 02 Aug 2007 06:00:00 PDT
An international team of researchers has published a benchmark study showing that gene expression in several animal models of Huntington's Disease (HD) closely resembles that of human HD patients.The results, published August 1, 2007, in the journal Human Molecular Genetics, validate the applicability of using animal models to study human disease and will have important consequences for the pertinence of these models in preclinical drug testing.
Medivation Announces Treatment Of First Patient In Phase 2 Trial Of Dimebon(TM) In Huntington's Disease published
Tue, 31 Jul 2007 00:00:00 PDT
Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in its Phase 2 trial of Dimebon(TM) to treat Huntington's disease. Medivation has expanded patient enrollment in the trial by 20 percent -- to 90 patients -- in order to enhance the ability to detect differences between Dimebon and placebo.
Drug Protects Brain Cells In Huntington's Disease Model published
Wed, 25 Jul 2007 00:00:00 PDT
A drug used in some countries to treat the symptoms of Huntington's disease prevents death of brain cells in mice genetically engineered to mimic the hereditary condition, UT Southwestern Medical Center researchers have found. The research sheds light on the biochemical mechanisms involved in the disease and suggests new avenues of study for preventing brain-cell death in at-risk people before symptoms appear.
Huntington's Disease Sufferers Need Focussed Management Of Sleep Symptoms In Their Treatment published
Fri, 20 Jul 2007 07:00:00 PDT
Mice carrying the genetic mutation that causes Huntington's Disease (HD) showed marked improvements in alertness and their ability to learn after they were given drugs that put them to sleep.Researchers at the University of Cambridge found that daily treatments of Alprazolam or chloral hydrate, two different sedative drugs, enabled them to develop a regular sleep pattern and improved their cognitive function -- their ability to understand and act on information.
Avicena To Advance Huntington's Disease Clinical Program Into Phase III published
Fri, 29 Jun 2007 00:00:00 PDT
Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today the selection of the optimal dose of HD-02, its novel drug candidate for the treatment of Huntington's Disease. This dose was determined in an open-label dose escalation study, led by Dr. Steven Hersch and Dr.
Medicine To Alleviate Huntington's? published
Sun, 17 Jun 2007 00:00:00 PDT
Huntington's disease is a hereditary disorder that primarily affects the brain, leading to death within just over a decade. There is no treatment for the disease at present, but researchers at Lund University in Sweden believe that a medicine used for Alzheimer's disease could alleviate some of the symptoms.Huntington's disease is caused by a mutation of a gene that the produces the Huntington protein. This protein influences a number of processes in the cells of the brain.
Avicena To Present Its Huntington's Disease Clinical Program At The Huntington's Disease Of America Society 22nd Annual Convention published
Sat, 16 Jun 2007 00:00:00 PDT
Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company focused on commercializing its proprietary cellular energy modulation technology, announced today its participation at the Huntington's Disease of America Society's 22nd Annual Convention, which will take place June 15 - 17, 2007 in Oklahoma City, OK.
Britain To Go Ahead With Human-Animal Embryos For Research published
Fri, 18 May 2007 00:00:00 PDT
The British government published its draft bill to overhaul the 1990 Human Fertilisation and Embryology Act this week and it differs from the White Paper introduced late last year in that research using part human part animal embryos is to be allowed after all.
)
|
|
